Press release
Gilead and Tentarix to Discover and Develop Novel Therapies to Address Unmet Medical Needs Across Cancer and Inflammation
– Collaboration Combines Gilead’s Oncology and Inflammation Expertise and Tentarix’s Tentacles™ Platform – – Gilead Receives Exclusive Rights to Acquire
About this update from Gilead Sciences, Inc.
[{"type":"text","content":"\n– Collaboration Combines Gilead’s Oncology and Inflammation Expertise and Tentarix’s Tentacles™ Platform –\n\n\n– Gilead Receives Exclusive Rights to Acquire Novel Therapies From this Collaboration –\n\n\n FOSTER CITY, Calif. & SAN DIEGO--(BUSINESS WIRE)--\nGilead Sciences, Inc. (Nasdaq:GILD) and Tentarix Biotherapeutics today announced that the companies established three multi-year collaborations leveraging Tentarix’s proprietary Tentacles™ platform to discover and develop multi-functional, conditional protein therapeutics for oncology and inflammatory diseases. Designed to enhance both therapeutic benefit and safety, these molecules have the potential to conditionally target immune cells related to disease pathways without activating other immune cells that may create adverse events.\n\nThis press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230814981551/en/\n“At Gilead, a key area of our research strategy is addressing immune dysregulation in oncology and inflammatory diseases,” said Flavius Martin, M.D., Executive Vice President, Research, Gilead Sciences. “This early-stage collaboration with Tentarix will be highly synergistic to our ongoing efforts, building upon our growing strength in protein therapeutics, and may provide access to next-generation, multi-specific biologics.”\n\n\n“This collaboration is part of our strategy to join forces with innovators, like Gilead, who can help us rapidly advance new medicines to the clinic,” said Paul Grayson, President and CEO of Tentarix Biotherapeutics. “Our technology has great promise and collaborating with Gilead to build out this pipeline helps broaden the development of multi-functional, antibody-based therapeutics, providing an excellent mechanism to validate our science with the ultimate goal of bringing these potential medicines to patients faster.”\n\n\nAcross the three collaborations, Tentarix will receive upfront payments and an equity investment from Gilead totaling $66 million. In addition, Gilead has the option to acquire up to three select Tentarix subsidiaries containing the programs developed under the collaborations for $80 million per subsidiary.\n\n\nBeginning in the first quarter of 2022, consistent with recent industry communications from the U.S. Securities and Exchange Commission (SEC), Gilead no longer...